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The mechanism by which hyaluronic acid (HA)-bearing lipoplexes target the A549 lung cancer cell 
line was evaluated. For this purpose, cationic liposomes targeting the CD44 receptor were designed 
thanks to the incorporation in their composition of a conjugate between high molecular weight HA 
and the lipid DOPE (HA-DOPE). Liposomes containing HA-DOPE were complexed at different 
lipids:DNA ratios with a reporter plasmid encoding the green fluorescent protein (GFP). Diameter, 
zeta potential, lipoplex stability and DNA protection from nucleases have been determined. 
Lipids:DNA ratios of 2, 4 and 6 provided a diameter around 250 nm with a zeta potential of − 30 mV. 
The strength of lipids:DNA interaction and the fraction of DNA protected from enzymatic 
degradation increased with the lipids:DNA ratio. 2D-immunoelectrophoresis demonstrated the low 
capacity to activate the C3 fraction of the complement system of any of these three ratios, with and 
without HA-DOPE. Transfection efficiency in the presence of 0, 10 and 15% of HA-DOPE or 
unconjugated HA, was determined on the CD44-expressing A549 cells by flow cytometry. 
Lipoplexes at a lipids:DNA ratio of 2 containing 10% (w/w) of HA-DOPE were the most efficient 
for transfection. The maximal level of GFP expression was obtained after 6 h of incubation 
demonstrating a slow transfection kinetics of lipoplexes. Finally, lipoplex cellular uptake, measured 
indirectly by the level of transfection using flow cytometry and validated by fluorescence microscopy, 
was shown to be mediated by the CD44 receptor and caveolae. These results demonstrate the strong 




Lipoplexes; Hyaluronic acid; A549; CD44; Endocytosis;  Complement activation 
  
1. Introduction 
Designing non‐viral gene delivery systems has been over the last two decades an important research 
area aiming to improve both stability and efficiency of the delivered plasmid DNA [1]. Development 
of carriers mediating safe and efficient gene transfer has been required to reach therapeutic levels of 
protein expression. In such context, synthetic vectors have emerged as an attractive strategy as they 
are able to protect DNA from nuclease degradation and to induce its condensation therefore reducing 
its size and making their cell uptake possible. Among the non-viral gene delivery systems, cationic 
liposomes have been widely investigated. Their main advantages include low immunogenicity [2] 
and toxicity [3] and [4] as compared to viral vectors [5] and [6] and their potential to transfect diverse 
tissues and cell types [4], [5], [6] and [7]. Nevertheless, several observations have limited the use in 
clinics of cationic lipid delivery systems. At first, it was observed in vivo in animal models that they 
aggregate in serum and therefore, accumulate in organs of the mononuclear phagocyte system (MPS), 
being taken up by macrophages [8]. When covering lipoplexes by polyethyleneglycol (PEG) to 
reduce opsonisation and MPS uptake, a decrease of transfection efficiency was observed in vitro 
[9] and [10]. Moreover, it was shown that the use of PEG combined with liposomal formulations 
containing DNA makes them less efficient in vitro [9] and more immunogenic [11]. 
Hyaluronic acid (HA) is a glycosaminoglycan composed of non-esterified disaccharidic units of N-
acetylglucosamine and glucuronic acid chains alternately β1→4 and β1→3. It is the major component 
of the extracellular matrix, being therefore ubiquitous. Contrary to HA oligomers, the native high 
molecular weight HA does not induce expression of genes involved in proliferation or inflammation 
[12] and counteracts proangiogenic effects of the oligomers [13]. Even if native HA can activate some 
signaling pathways, this occurs at levels far lower than with HA oligomers [12]. All this has led to 
consider the high molecular weight HA as a “bioinert” component [14]. Most interestingly, HA was 
proposed as an alternative to PEG, to target liposomes encapsulating small molecules [15] and [16] 
or lipoplexes [17]. HA presents two advantages. First it can be an addressing molecule due to the 
expression of its membrane receptor, CD44, on tumor initiating cells (TIC) [18] and second because 
it is a hydrophilic polymer, it could prevent opsonin adsorption by steric repulsion allowing to reduce 
MPS uptake. 
We have synthesized a HA-DOPE conjugate which was included in lipoplexes demonstrating an 
improved transfection of breast cancer cells when these cells express the CD44 receptor [17]. These 
first results have demonstrated that using HA was indeed relevant for increasing the expression of a 
reporter gene in a cancer cell line. However, the extent of HA anchoring to lipoplexes and the 
mechanism of uptake remained open questions. The present report aims to produce the evidence of 
the presence of HA on lipoplex surface and clarify their mechanism of internalization through their 
interaction with the CD44 receptor on the A549 lung cancer cell line. 
2. Materials and methods 
2.1. Materials 
High molecular weight hyaluronic acid (HA) (sodium salt, 1600 kDa, purity of 95%) was purchased 
from Acros organics (Geel, Belgium). L-alpha-dioleylphosphatidylethanolamine (DOPE) and 
phosphatidylethanolamine conjugated to rhodamine (PE-rhodamine) were provided by Avanti Polar 
Lipids distributed by Sigma Aldrich (Saint Quentin Fallavier, France). The cationic lipid [2-(2-
3didodecyloxypropyl)hydroxyethyl]ammonium bromide (DE) was synthesized as described [19]. 
Capillary electrophoresis of the conjugate shows that all DOPE molecules were linked to HA and that 
there was no free HA in the mixture. Research grade plasmid pCMV-GFP pF463 (3487 bp) was 
purchased from Plasmid factory (Bielefeld, Germany). 
2.2. Lipoplex preparation 
To prepare liposomes, a thin lipid film was obtained by evaporation under vacuum of a chloroformic 
solution of an equal mixture (w/w) of DE and DOPE using a rotative evaporator. The lipid film was 
then hydrated with an aqueous solution of 10% (w/v) HA-DOPE conjugate at a final concentration 
of 1 mg/mL during 8 min under vortex stirring until complete film detachment and formation of a 
liposomal suspension. Various volumes of liposomal suspension were gently added to a 1 mg/mL 
pCMV-GFP solution at different lipids:DNA ratios. Complexation under nitrogen, at ambient 
temperature, was carried out during at least 1 h before use. Fluorescently labeled lipoplexes were 
prepared similarly by substituting 6% (w/w) of DOPE by PE-rhodamine. 
2.3. Differential scanning calorimetry 
Differential scanning calorimetry (DSC) analysis was performed on hydrated samples using a 
differential scanning calorimeter (DSC 7, Perkin Elmer, USA) equipped with the Pyris software. 12 h 
before the experiment, lipid films of DOPE (10 mg) were hydrated either with 100 µL MilliQ water 
or with 100 µL of a 10 mg/mL HA-DOPE solution. Then about 4 mg of accurately weighted samples 
were introduced into a 40 µL pan and analyzed. DSC runs were conducted from − 40 °C to + 90 °C 
at a rate of 10 °C/min. Calibration was achieved using n-decane (Tm = − 28.11 °C) as well as indium 
(Tm = 156.83 °C). Enthalpies were normalized with respect to DOPE weight in the sample. 
2.4. Capillary electrophoresis 
A Beckman P/ACE System 5500 was used with an uncoated fused silica capillary (length to detector: 
57 cm and internal diameter: 75 µm) on normal polarity. Electrophoresis conditions to analyze HA-
DOPE conjugate were derived from Grimshaw et al. for the assay of HA [20]. The capillary was first 
conditioned by 4 successive rinsings for 5 min each with water, 1 M NaOH, 0.1 M NaOH and back 
to water. Then before each analysis, the capillary was washed with successively (and at 20 psi), water 
for 1 min, 0.1 M NaOH for 2 min, water for 1 min, 0.1 M HCl for 2 min, water for 2 min and finally 
equilibrated with the background electrolyte for 2 min. The separation buffer was 40 mM sodium 
tetraborate containing 40 mM of sodium dodecyl sulfate (SDS). Sample injection was done under 
nitrogen at 0.5 psi for 2 s. All samples were adjusted at a concentration of 0.5 mg/mL of HA or HA-
DOPE by evaporation under vacuum using an Eppendorf Concentrator® at 30 °C, which 
concentrated liposomes 5-fold and lipoplexes 8-fold. This step was validated after verification by 
dynamic light scattering that no modification of the diameter and zeta potential occurred during this 
concentration step (data not shown). Detection wavelength was 200 nm and the voltage applied was 
18 kV. The capillary was maintained at 25 °C during electrophoresis. Experiments were performed 
at least in duplicate. 
2.5. Diameter and zeta potential measurement 
Diameter and zeta potential were determined with a Zetasizer Nano Zs (Malvern Instruments Ltd, 
Malvern, UK). Before each measurement, liposomes and lipoplexes were diluted at 2% (v/v) in 1 mM 
NaCl. Measurements were carried out in triplicate at 25 °C on three independent preparations. Size 
measurements were also performed in cell culture media. 
2.6. Gel migration assay 
After addition of BB5X blue (10 mM Tris pH 7.4, 2 mM EDTA, 25% glycerol, 0.02% bromophenol 
blue, and 0.02% xylene cyanol), 2 µg of plasmid, free or complexed to liposomes at different 
lipids:DNA ratios (1, 2, 3, 4, 6, 8) were loaded on a 1% agarose gel in TBE1X buffer (89 mM Tris, 
89 mM boric acid, 2 mM EDTA disodium salt) containing ethidium bromide, and migrated at 100 V 
for 20 min. DNA which was not bound to liposomes migrated under electric field. 
2.7. Protection against degradation by nucleases 
2 µg of plasmid complexed or not to liposomes at different lipids:DNA ratios (1, 2, 3, 4, 6, 8) were 
digested by 2 IU of DNase I (Invitrogen, Cergy Pontoise, France) for 30 min at 37 °C in the presence 
of 20 mM MgCl2. The digestion was stopped by heating the mixture at 60 °C for 10 min in the 
presence of 50 mM EDTA. Lipids were then solubilized in an SDS solution up to a final detergent 
concentration of 17 mM. After vigorous agitation, samples were centrifuged at 10,000 rpm for 5 min 
then heated at 75 °C for 15 min. Each sample was loaded on a 1% agarose gel in TBE 1X as described 
for gel migration assay. 
2.8. Evaluation of activation of C3 protein of the complement system 
Conversion of plasmatic C3 protein into C3b and C3a fragments, signing an activation of the 
complement system, was evaluated by 2-D immunoelectrophoresis using a polyclonal antibody to 
human C3 as described [21]. Lipoplexes of lipids:DNA ratios of 2, 4 and 6 with or without HA-DOPE 
were prepared, then concentrated 10-fold at 30 °C using an Eppendorf Concentrator® in order to 
obtain a sufficient specific surface. Veronal Buffer Saline (VBS) containing 0.15 mM Ca2 + and 
0.5 mM Mg2 + ions (VBS2 +) and VBS containing 40 mM ethylenediaminetetraacetic acid (VBS–
EDTA) were prepared as described by Kazatchkine et al. [22]. A volume of suspension equivalent to 
a specific surface of 230 cm2 (calculated by Sspecific=6×mD×d where D is the 
average diameter, m is the mass contained in the sample, and d is the density) was incubated under 
gentle agitation for 1 h at 37 °C with 50 µL of human serum (EFS Ile-de-France, Kremlin-Bicêtre) 
and 50 µL of VBS2 +. All experiments were done with the same human serum which was tested for 
functionality prior to be used in the present test. The absence of lipoplex size modification in this 
medium was checked. Briefly, samples were subjected to a first electrophoresis on 1% agarose gel in 
tricine buffer, then deposited on a Gelbond® film coated with agarose gel containing a polyclonal 
antibody to human C3 (Sigma, France) at 0.1 mg/mL. This polyclonal antibody can recognize the 
native and activated form of the protein C3. The samples were then subjected to a second dimension 
electrophoresis, followed by protein precipitation and fixation in 0.15 M NaCl and further drying. 
Films were finally stained with coomassie blue to reveal the presence of native C3, and lower 
molecular weight active fragments C3a and C3b precipitated with the antibody. Each sample was 
analyzed three times across the whole process. Activation of the C3 protein was expressed as the 
complement activation factor (CAF) defined as the ratio of the peak surface of C3a + C3b detected 
on the plate over the sum of the peaks surface of C3 and C3a + b, using the following equation: 
CAF=(C3a+C3b)C3+(C3a+C3b). Areas under the peaks were measured using 
ImageJ software. 
2.9. Cell culture 
Human lung cancer A549 cells (ATCC CCL-185) were cultured in Roswell Park Memorial Institute 
(RPMI) Medium 1640 (Lonza, Belgium) supplemented with 10% fetal bovine serum (FBS, Lonza, 
Belgium), 50 U.mL− 1 penicillin, 50 U.mL− 1 streptomycin and 1% glutamine. Cells were maintained 
at 37 °C in a humidified atmosphere with 5% CO2. 
2.10. Assessment of CD44 expression 
A549 samples for assessment of CD44 expression were prepared as described before [17]. For all 
flow cytometry experiments, cells were excited at 488 nm with an argon laser source, and emission 
was analyzed through a 510/20 nm band-pass filter for GFP, a 529/28 nm band-pass filter for FITC. 
Doublets were eliminated by pulse discrimination. The cytometer was a MoFlo XDP (Beckman 
Coulter) driven by the Summit software. Analysis was done in duplicate with 10,000 cells measured 
in each sample. Results are given as a percentage of cells above fluorescence threshold. 
2.11. Cell transfection 
Cells were seeded in 500 µL of growth medium (7.5 × 104 cells.mL− 1) in 24-well plates (TPP, 
Switzerland) and pre-incubated for 24 h. Just before treatment by various lipoplexes formulations 
(lipids:DNA ratios of 2, 4 and 6; without or with 10 and 15% of HA-DOPE or unconjugated HA) for 
24 h at 10 µg/mL, cells were washed and recovered with medium without serum. Lipofectin®, a 
formulation of DOTMA:DOPE (1:1), was used as a positive control. Cells were washed and medium 
with FBS was introduced 24 h after transfection. To study the transfection kinetics, medium was 
removed 2, 6 or 24 h after the beginning of the treatment by lipoplexes of ratio 2 with 10% HA-
DOPE. Medium containing FBS was added 24 h after transfection. Samples were prepared 54 h after 
transfection for flow cytometry experiments. After detachment, cells were washed by PBS and then 
recovered in 600 µL of 1% paraformaldehyde in PBS at 4 °C. Analyses were achieved by flow 
cytometry as described for assessment of CD44 expression. 5000 cells were measured per sample and 
each analysis was done in triplicate. The normalized transfection efficacy index (NTEI) was 
calculated according to the following equation: 
NTEI=%ofsinguletlivingcellswhichexpressGFP×fluorescenceintensityofGFP+cellsfluorescenceinte
nsityofGFP−cells 
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Moreover, results of kinetics study expressed in NTEI are also presented in percentage, taking into 
account that the value of NTEI at 24 h is fixed at 100%. 
2.12. Endocytosis pathways 
The concentrations of the endocytic inhibitors were set after the following optimization. Each 
inhibitor was incubated at various concentrations (1, 6, 15, 25, 50 µM chlorpromazine; 1, 4, 7 µM 
filipin; 50, 75, 100, 200 µM genistein; 2–7 mM methylβcyclodextrin; 0.5, 1.6, 2, 10 µg/mL CD44 
antibody) and the cell viability was monitored by flow cytometry. The maximal concentration 
associated to absence of toxicity was then selected for each inhibitor, except for methylβcyclodextrin 
which was found toxic at all tested concentrations. 
A549 cells were pretreated with aqueous solutions of 1 µM chlorpromazine, high molecular weight 
HA in 50‐fold the amount contained in lipoplexes 10% HA, 1.6 µg/mL CD44 antibody (clone A3D8), 
50 µM genistein, 1 µM filipin (Sigma Aldrich, France) (a control experiment was performed 
including the same volume of ethanol than what is contained in filipin solution). After 1 h of 
incubation at 37 °C in a humidified atmosphere with 5% CO2 (except 2 h for CD44 antibody), 
lipoplexes of ratio 2 with 10% HA-DOPE were added (10 µg/mL). Medium was removed after 6 h. 
Medium containing FBS was added 24 h after transfection. Samples for flow cytometry analysis were 
prepared as previously described for study of cell transfection 54 h after transfection. Results 
expressed in NTEI are presented in percentage, taking as reference for 100%, the NTEI of control 
without inhibitory treatment. These studies were coupled with fluorescence microscopy. In vitro 
imaging acquisition was performed with a Zeiss videomicroscope (Axio Observer Z1) equipped with 
an incubator (temperature and CO2 controlled) in order to collect the green fluorescence on living 
cells. All images were acquired with a 20 ×/0.8 plan-Apochromat objective lens using a 470 nm LED 
for excitation and a 505–550 nm band pass filter to quantify the emission of fluorescence. 
Videomicroscope was coupled with a MRm CCD camera. 
2.13. Intracellular trafficking 
The uptake and intracellular trafficking of lipoplexes (at a lipids:DNA ratio of 2 with 10% HA-DOPE) 
was investigated on A549 cells using confocal laser scanning microscopy. A549 cells were seeded at 
35,000 cells/cm2 on coverslips and cultured for 24 h at 37 °C, 5% CO2. The cells were then treated 
with fluorescent lipoplexes at the final concentration of 10 µg/mL. After 2 h, 6 h or 24 h incubation 
cells were rinsed with PBS and fixed by addition of 800 µL of 4% paraformaldehyde in PBS (w/v) 
during 20 min. After washing with PBS, 10 µL of Vectashield® mounting medium for fluorescence 
(Vector Laboratories, Inc., Burlingame, CA, USA) was used to prepare the slides. Fluorescence 
experiments were performed with a confocal laser scanning microscope LSM 510-Meta (Zeiss, 
Germany) using a 63 ×/1.4 plan-Apochromat objective lens, a helium neon laser (excitation 
wavelength 543 nm) and a long pass emission filter LP 560 nm. The pinhole was set at 1.0 Airy unit 
(0.8 µm optical slice thickness). 12 bit numerical images were acquired with LSM 510 software 
version 3.2. Red intensity profiles were plot with Image J (version 1.42) software (NIH, USA) and 
the 3D reconstructions and surface rendering were generated using IMARIS 7.1.1 (Bitplane, Zurich) 
imaging software. 
3. Results 
3.1. Characterization of HA-DOPE lipoplexes 
The physico-chemical studies aimed to evaluate the presence of the conjugate within liposome 
structure. Differential scanning calorimetry analysis of DOPE demonstrated that the endotherm of 
gel to liquid crystal phase transition shifted from − 10.30 °C with water or unconjugated HA to 
− 8.97 °C with HA-DOPE (Supplementary Fig. S1). Assessment of the HA-DOPE purity and 
determination of the HA fraction bound to liposomes or lipoplexes were carried out by capillary 
electrophoresis by determination of the free fraction of HA (Fig. 1). 
 
Fig. 1.  
Electropherogramms obtained by capillary electrophoresis of 0.5 mg/mL unconjugated HA, 
0.5 mg/mL HA-DOPE, liposomes with unconjugated HA or HA-DOPE or without any HA, 
lipoplexes with unconjugated HA or HA-DOPE. 
HA-DOPE migration time was 9 min and the electrophoretic profile did not display the characteristic 
peak of unconjugated HA which appears at 12 min, demonstrating the absence of free HA in the 
conjugate. 80 ± 3.1% of unconjugated HA is bound to liposomes, but after DNA addition only 
17 ± 1.3% remains associated to them. However in the case of HA-DOPE, only 61 ± 1.0% of HA-
DOPE is associated to liposomes, but 42 ± 10.7% remains associated after lipoplex formation. 
Whereas the liposome diameter was similar at around 400 nm with or without HA, significant 
reduction of the zeta potential was observed when liposomes are associated to 10% of HA-DOPE or 
unconjugated HA compared to plain liposomes (p < 0.0001) (Fig. 2). 
 
Fig. 2.  
Diameters and zeta potentials of liposomes, compared to lipoplexes at a lipids:DNA ratio of 
2 containing or not 10% HA-DOPE or unconjugated HA (un-HA) (vs. liposomes without HA: 
**** p < 0.0001; vs. lipoplexes without HA: §§ p < 0.01; §§§ p < 0.001 ) (n = 3). 
Addition of DNA to liposomes decreased their diameter in the same way for lipoplexes formulations 
without HA or with 10% HA-DOPE, but not for lipoplexes with 10% unconjugated HA. Presence of 
DNA lowers zeta potential values to around − 30 mV. Finally, the diameter and zeta potential values 
were similar between lipids:DNA ratios varying from 1 to 6 in presence of HA-DOPE, being around 
300 nm and − 30 mV (Fig. 3). 
 
Fig. 3.  
Diameters and zeta potentials of lipoplexes at different lipids:DNA ratios (1, 2, 3, 4, 6, 8) 
(n = 3 on 3 independent preparations). 
For the highest lipids:DNA ratio tested, 8, the diameter and the zeta potential increased respectively 
to values of 361 ± 156 nm and − 21.0 ± 2.7 mV. 
3.2. DNA stability and DNA–liposome interactions 
Assessment of the interaction between DNA and liposomes was carried out by electrophoresis on 
agarose gel (Fig. 4). 
 
Fig. 4.  
1% agarose gel showing profile migration of plasmid in lipoplexes at different lipids:DNA 
ratios (1, 2, 3, 4, 6, 8) with 10% HA-DOPE, at a constant amount of DNA and comparison 
with free DNA. The non‐migrating plasmid is on the top of the gel image. DNA bands on the 
bottom are the fraction of DNA that can be separated from the lipoplexes by electrophoresis. 
DNA migration shows that when the lipids:DNA ratio increased, the associated fraction increased 
and the quantity of free or weakly associated fractions was reduced. A similar experiment was carried 
out after incubation of lipoplexes with DNAse I (Fig. 5). 
 
Fig. 5.  
1% agarose gel showing migration profile of plasmid in lipoplexes for different lipids:DNA 
ratios (1, 2, 3, 4, 6, 8) with 10% HA-DOPE at constant amount of DNA after DNAse I 
exposition (in unit sufficient to total digestion as shown by positive control). Histograms 
present band intensity determined thanks to ImageJ software (% compared to the negative 
control set at 100%). 
This experiment demonstrates that the more the cationic lipids, the better the protection against 
DNAse I is. Indeed protection increased from 3% to 77% with lipids:DNA ratios varying respectively 
from 1 to 6. The protection effect then decreased slightly, being 60% for a lipids:DNA ratio of 8. 
Noteworthy, the diameter of lipoplexes evaluated on cells in the following (lipids:DNA ratio of 2, 
10% HA-DOPE) did not differ significantly in the serum-containing cell culture media 
(249 ± 27 nm). 
3.3. Evaluation of the activation of the C3 protein of the complement system 
Complement activation was determined by 2D-immunoelectrophoresis of C3 on lipoplexes made 
with three lipids:DNA ratios of 2, 4, 6 with or without 10% of HA-DOPE (Fig. 6). 
 Fig. 6.  
Activation factor of the C3 protein (CAF) values for lipoplexes at lipids:DNA ratios of 2, 4, 
6, with or without 10% of HA-DOPE, after substraction of the CAF value corresponding to 
spontaneous activation of serum (100% matches for CAF value of positive controls at the 
specific area of 230 cm2) (with HA-DOPE vs without HA-DOPE: ** p < 0.01; *** p < 0.001). 
Although lipoplexes containing HA-DOPE with lipids:DNA ratios of 4 and 6 give higher CAF values 
than the respective samples without HA-DOPE, all formulations tested possess CAF values under 
50%, which corresponds to a low activation of the complement (incubation time of 1 h, a specific 
surface value of 230 cm2). 
3.4. Transfection of CD44-expressing A549 cells 
As seen by flow cytometry, 99.98% of A549 cells express CD44 on their surface (Fig. S2). Cell 
viability measured by MTT was always above 80% for concentration of lipoplexes up to 10 µg/mL 
in culture medium, independently of lipids:DNA ratio and whether HA-DOPE was present or not in 
the formulation (data not shown). The percentage of transfected cells reached 17% at 2 h and 
plateaued at 33% from 6 h (Fig. S3). After 2 and 6 h of incubation with lipoplexes, the NTEI reached 
respectively 50 and 100% of the maximal level equivalent to the one obtained with 24 h of incubation 
(Figure S3). Comparison of different lipids:DNA ratios shows that, despite an equivalent amount of 
intact DNA, the lipids:DNA ratios of 2 and 4 are more effective than 6 (Fig. 7). 
 Fig. 7.  
Normalized transfection efficacy index (NTEI) of lipoplexes, as a function of the lipids:DNA 
ratio (2, 4, 6), the mode (conjugated or unconjugated) and the rate (0, 10 or 15%) of HA 
incorporation, and comparison with Lipofectin® at the same lipids:DNA ratios (2, 4, 6) (vs 
Lipofectin® at same ratio: * p < 0.05; ** p < 0.01; *** p < 0.001; vs unconjugated HA at 
same ratio: §§ p < 0.01; n = 3). 
For these two more efficient ratios, the addition of 10% HA-DOPE, but not 15%, increased 
significantly the GFP expression. Lipids:DNA ratio of 4 containing 10% HA-DOPE and 
unconjugated HA present the same GFP expression levels as Lipofectin®. For the ratio 2 containing 
10% of HA, a larger transfection efficiency was observed compared to other treatment and 
particularly compared to unconjugated HA (p < 0.01) and Lipofectin® (p < 0.05). 
3.5. Determination of endocytosis pathways 
Cell treatment with HA 50X, which saturates CD44, or CD44 antibody which blocks the HA receptor, 
both resulted in a 40% decrease of GFP expression (Fig. 8). 
 Fig. 8.  
Effects of endocytosis-interfering treatments on GFP expression studied by flow cytometry. 
A549 were incubated for 6 h with lipoplexes with a lipids:DNA ratio of 2 containing 10% of 
HA-DOPE, 1 h (except 2 h for CD44 antibody) after pretreatment with 1 µM chlorpromazine, 
1 µM filipin (+ control ethanol alone), 50 µM genistein, excess of high molecular weight HA 
(50X), and 10 µg/mL CD44 antibody. NTEI results are expressed in percentage with NTEI of 
control cells set at 100% (* p < 0.05; ** p < 0.01; *** p < 0.001; n = 3). 
Incubation with filipin, an inhibitor of caveolae-mediated endocytosis, reduces the transfection by 
60%. Moreover, when genistein, another inhibitor of this internalization pathway, is used, GFP 
expression is lowered by 90%. In contrast, using chlorpromazine, a clathrin-mediated endocytosis 
inhibitor, transfection levels were not changed. Microscopy experiments enable to verify visually the 
cell integrity (no dysmorphy or autofluorescent dead cells) and coincide with flow cytometry results 
(Supplementary Fig. S4). 
3.6. Intracellular trafficking 
The uptake and intracellular trafficking of lipoplexes (lipids:DNA ratio of 2, 10% HA-DOPE, 
containing PE-rhodamine) in A549 cells was assessed on 0.8 µm thick slices by confocal microscopy 
(Fig. 9, and Supplementary Fig. S5 for 3D reconstructions). The observations (Fig. 9A) and intensity 
profiles (Fig. 9B) show a progressive uptake of lipoplexes, the global fluorescence increasing from 
2 h to 6 h and 24 h incubation. The fluorescence pattern also changes during incubation. After 2 h, 
cells mostly show a cytoplasmic intense punctuated fluorescence (and a slight diffuse fluorescence), 
consistent with the presence of endosomal vesicles containing lipoplexes. After 6 h and 24 h, between 
one third and one half of the cells exhibit intense cytoplasmic diffuse fluorescence, indicating the 
presence of the fluorescent lipids in the cytosol. 
 Fig. 9.  
A. Uptake and intracellular trafficking of fluorescent lipoplexes (lipids:DNA ratio of 2, 10% 
HA-DOPE) after 2 h (left), 6 h (middle) and 24 h (right) incubation with A549 cells, as 
evaluated by confocal laser scanning microscopy. For each images, composed of (z-axis) 
projection of three median optical slices of 0.8 µm thick, cells with a mininum fluorescence 
intensity (m) and a maximal fluorescence intensity (M) are shown. B. Red intensity profiles 
of m and M cells, are respectively presented on the left and right graphs (at 2 h (red), 6 h 
(blue) and 24 h (green) incubation). 
4. Discussion 
The present report was aiming to understand the mechanism of interaction of HA-bearing lipoplexes 
with CD44 receptor-expressing cells. The first underlying basic assumption of our study was that 
HA-DOPE conjugate could be inserted into vesicle bilayers thanks to its hydrophobic moiety. The 
HA-DOPE conjugate is obtained through the creation of an amidic bond between the carboxylic 
group of HA and the amino group of DOPE. However, the affinity between the conjugate and lipids 
forming the liposome bilayer was questionable regarding the large difference of molecular weight 
existing between DOPE (740 g.mol− 1) and HA (1.6 × 106 g.mol− 1). Differential scanning calorimetry 
revealed a difference of behavior between unconjugated HA and HA conjugated to DOPE suggesting 
that DOPE covalently linked to HA interacts with DOPE, being therefore able to play the role of 
anchor in the lipid membrane. 
Previous studies by Surace et al. [17] have shown that 10% HA-DOPE (w/w) was optimal for 
transfection of MDA-MB231 breast cancer cells expressing CD44. We have therefore used this 
amount of conjugate and formulated lipoplexes at different lipids:DNA ratios. Whereas all lipoplex 
formulations were negatively charged, a reduction of the zeta potential was only seen for the highest 
lipids:DNA ratio of 8. Nevertheless, at these lipids:DNA ratios, the size distribution was polydisperse. 
It was shown previously that lipoplex size and heterogeneity of the structures both appear to increase 
along with the lipids:DNA ratio probably because the density of the complexes decreases as the 
lipids:DNA ratio increases [23]. Nevertheless, estimation of lipoplex stability by gel migration 
reveals that the more lipids were introduced to a constant amount of DNA, the stronger the 
interactions in lipoplexes. At lowest lipids:DNA ratios, the low amount of cationic charges left a large 
part of DNA free from any interaction. However, capillary electrophoresis shows that there is no 
migration of free DNA at a ratio of 2 (no peak at 32 min as control DNA alone, data not shown). At 
high lipids:DNA ratios of 6 or 8, the amount of free DNA was low meaning that all charges from 
DNA are involved in the interaction with cationic liposomes. These data are of high interest since 
even with a high amount of cationic lipids, the particles remain negatively charged. Cationic charges 
are known to promote strong instabilities in the presence of serum leading to aggregation [24]. This 
phenomena would disappear in presence of the lipoplexes designed here. Finally, as the amount of 
cationic lipids increases, an increase of the protection ability against DNAse I is observed with a 
maximum of protection close to 80% for a lipids:DNA ratio of 6. This protection then decreases at 
the ratio of 8 where the density of the lipoplexes is supposed to be lower (as shown by size 
measurements), allowing more access to the degrading enzymes. In relation to these data, the lipoplex 
formulations of ratios 2, 4 and 6 were considered as the most promising for further experiments. 
We have determined whether HA could modulate complement activation when added in the 
formulations. This was done by the evaluation of protein C3 activation. This protein of the 
complement cascade is activated whatever the route of initiation of the activation of the complement 
system. Activation of the protein C3 is a good indicator on the capacity of macrophages of the MPS 
to phagocytose the drug carrier. Despite an increase of complement activation for the ratios 4 and 6 
formulated with HA-DOPE compared to lipoplexes formulated without the conjugate, all 
formulations are low activators of the complement system, the formulation prepared at a lipids:DNA 
ratio of 2 being the less activating one. These data are in accordance with those of Mizrahy et al. 
reporting that unilamellar liposomes of 100 nm, containing 1500 kDa HA and composed of 
PC:Chol:DPPE slightly enhance complement activation [25]. This slight increase of complement 
activation in the presence of HA-DOPE could be due to polysaccharidic nature of HA, even if it is 
the lowest activator of glycosaminoglycans [26]. Another explanation could involve the way HA-
DOPE is inserted in the lipid bilayer. Because more than one DOPE is linked on one chain of HA, 
the conjugate insertion could be obtained by more than one anchor, inducing the formation of a 
specific conformation of the HA around the lipoplexes which might be different from the classic 
brush or mushroom. In any case, our goal to obtain lipoplexes with a low activating profile was 
reached. This is further supported by observations by Plank et al. [27] showing the low complement 
activation potential of the cationic lipids used. Finally, it is noteworthy that the lipoplex surface area 
used in this experiment was more than four times higher than what could be present after 
administration in vivo in a mouse model. 
Transfection experiments were carried out on the A549 cancer cell line, which was shown in our 
hands to be a suitable model for targeting DNA because the totality of the cell population exhibits the 
CD44 membrane receptor [28]. Transfection efficiency of lipoplexes at different lipids:DNA ratios 
was tested at equivalent amount of intact DNA and using GFP plasmid as reporter gene. The optimal 
lipoplex formulation was the one containing 10% HA-DOPE at a lipids:DNA ratio of 2, which 
displayed a higher efficiency than lipoplexes without HA-DOPE, lipoplexes associated to 
unconjugated HA, and Lipofectin®. Moreover, when increasing the amount of HA-DOPE conjugate 
from 10 to 15%, the GFP expression dropped down to levels obtained with lipoplexes made without 
HA-DOPE. At this concentration, the amount of HA presented to cell might be too high to allow 
interaction with the CD44 receptor because of steric hindrance. These observations are supported by 
mechanistic studies demonstrating that when saturating CD44 receptor by an excess of HA or the 
CD44 epitope deadlock by antibody treatment, a strong reduction of GFP expression was observed. 
This also confirms the crucial role of the receptor in the endocytosis mediated process, as shown 
previously by us and others [25] and [29]. 
The more efficient formulation obtained at a lipids:DNA ratio of 2 with an amount of 10% HA was 
further characterized. Capillary electrophoresis was first used to indirectly quantify the amount of 
HA bound to the vesicles in the unconjugated form or conjugated to DOPE. The determination of the 
free fraction of HA compared to the total amount of HA added in formulations of ratio 2 shows that 
HA-DOPE binds to a lower extent to liposomes but strongly to lipoplexes as compared to 
liposomes/lipoplexes prepared with unconjugated HA. The use of HA-DOPE conjugate provides 
twice more association of HA to lipoplexes which could also explain the highest transfection 
efficiency of HA-DOPE containing lipoplexes. The presence of the anionic HA (conjugated or 
unconjugated) at the surface of cationic liposomes lowers the zeta potential values, demonstrating 
surface coverage. This external location is a prerequisite to confer cell specific targeting. We observed 
drastic size reduction when adding DNA to plain liposomes or liposomes containing HA-DOPE from 
values of around 400 nm down to 250 nm. Surprisingly, size reduction could not be observed with 
unconjugated HA. DNA that is negatively charged competes more efficiently with free negatively 
charged HA that is bound only electrostatically to cationic liposomes. Whereas when HA is associated 
to lipid bilayer through its DOPE moiety insertion, competition between HA and DNA is lower: HA-
DOPE does not interfere with lipoplex formation since it interacts mainly with liposomes by 
hydrophobic forces. Moreover, unconjugated HA inhibits lipoplex formation since HA is added 
before DNA in the process of lipoplex formation. This might explain why zeta potential values are 
more negative with lipoplexes containing unconjugated HA than with those containing HA-DOPE. 
The endocytosis pathways were finally explored by different endocytosis-interfering treatments. 
There was no inhibitory effect of chlorpromazine, a cationic amphiphilic drug, which causes the loss 
of coated pits from the surface of the cell and blocks the appearance of clathrin coats on endosomal 
membranes [30]. This excludes clathrin-mediated endocytosis from being the pathway considered for 
the internalization of HA-DOPE-bearing lipoplexes. Since the perturbation of the caveolae, that is 
rich in cholesterol, by filipin, a sterol binding agent or by genistein, a kinase inhibitor [31] induces a 
decrease of the GFP expression in A549 cells, caveolae appear as the main endocytosis pathway of 
HA-bearing lipoplexes. Moreover, when CD44 is neutralized, transfection is also lowered suggesting 
that this receptor plays a role in lipoplex uptake. Caveolin-mediated endocytosis was already shown 
to be activated in the case of HA interaction with CD44 [32], both caveolin [33] and CD44 [34] being 
present in lipid rafts domains. Inhibition of CD44 by an excess of HA or CD44 antibody are known 
to block one of the pathways for caveolin phosphorylation which is necessary to start the caveolae-
dependent endocytosis [32]. The reason why filipin and genistein are able to decrease in a larger 
manner the transfection level might be due to a higher inhibition of the caveolae-dependent 
endocytosis by cholesterol sequestration or perturbation of both dynamin and actin networks 
respectively, contrary to the inhibition of CD44 that impacts only a part of the caveolae process 
activation. Use of methylbetacyclodextrin in order to extract cholesterol was not possible as we 
observe cell dysmorphology and conclude to too much cytotoxicity on A549 whatever the 
concentration used. In A549 cells, clathrin-mediated endocytosis gives maximal levels of gene 
expression after an incubation period of 15 min, while maximal levels are being attained after 3 h for 
caveolae pathway [35]. The slow kinetics of GFP expression that we observed were typical for a 
caveolae-mediated internalization [35]. This caveolae mediated endocytosis is consistent with the 
internalization pathway of DMRIE:cholesterol (1:1) lipoplexes [36], but not with DOTAP lipoplexes 
that are internalized in A549 mainly by clathrin-mediated endocytosis [35]. Moreover our results are 
in accordance with others that show the ability of HA-bearing liposomes to interact with cells 
expressing CD44 [25] and [29]. 
Finally, the uptake and intracellular trafficking studies of fluorescent lipoplexes confirmed a 
progressive internalization associated with the formation of endosomes. The diffuse cytoplasmic 
fluorescence observed from 6 h indicates that lipoplexes are able to escape endosomes and reach the 
cytosol. Noteworthy, the plateau-like pattern from 6 h and the fraction of cells exhibiting intense 
diffuse cytoplasmic fluorescence is consistent with the transfection kinetics and fraction of cells 
transfected. 
The DE-based, HA-bearing lipoplexes based on HA-DOPE, which display an interesting stability in 
serum-containing media, are thus promising for further in vivo evaluation using an anticancer 
therapeutic gene. 
5. Conclusion 
Among the different ratios tested, one formulation has notably emerged from transfection screening: 
lipoplexes prepared at a lipids:DNA ratio of 2 containing 10% HA-DOPE. This HA-DOPE 
incorporation rate leads to the most efficient formulation while maintaining a low complement 
activation. Here we provide additional information showing the interest of lipoplexes containing an 
HA-DOPE conjugate, which confers affinity to HA and allows a lipid bilayer insertion. Secondly, 
HA-DOPE is of interest because of the higher amount of HA associated to lipoplexes. And finally, 
this conjugate improves the transfection efficiency obtained after internalization that could be 
mediated by the CD44 receptor. This last point confers an ability of being internalized by cells 





Figure S1.  
Study of the transition temperature from gel to liquid crystalline phase of DOPE hydrated by 
different solutions (HA-DOPE, unconjugated HA and water) by differential scanning 
calorimetry. The first peak of each thermogram corresponds to the transition temperature (Tm) 
of hydrated DOPE and the second to the water melting. The three curves correspond (from 
top to bottom) to DOPE film hydrated by an aqueous solution of HA-DOPE 10%, DOPE film 
hydrated by an aqueous solution of unconjugated HA 10% and to DOPE film hydrated by 
water. 
 
Figure S2.  
A549 were stained with IgG1-labeled FITC antibody (A) and CD44-labeled FITC antibody 
(B). Each sample was measured in duplicate (10,000 cells measured per aliquot). 
 Figure S3.  
A549 transfection kinetics of ratio lipids:DNA 2 containing 10% of HA-DOPE incubated for 
2, 6 or 24 h. Flow cytometry results of normalized transfection efficacy index (NTEI) are 
expressed as the percentage of GFP-expressing cells and as the percentage of the NTEI 
reached at 24 h (*** p < 0.001; n = 3). 
Figure S4.  
Fluorescence and bright field images of A549 cells all treated by lipoplexes at lipids:DNA 
ratios of 2 containing 10% HA-DOPE (except negative control called “without lipoplexes or 
inhibitors”), after different endocytosis-interfering treatments: chlorpromazine, filipin, 
genistein, CD44 antibody, excess of HA. 
 
 
Figure S5.   
Three-dimensional reconstructions after surface rendering of confocal laser scanning 
microscopy slices corresponding to ‘m’ and ‘M’ cells shown in Fig. 9, after 2 h, 6 h and 24 h 
incubation with fluorescent lipoplexes. 
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